Bausch + Lomb Q2: 40% EPS Growth Says the Turnaround Is Working-But the Valuation Math Is the Real Test

Bausch Health's Q2 shows B+L's turnaround is moving from repair to proof

This quarter matters because B+L is no longer just trying to stop the bleeding; it is being asked to show the momentum is repeatable. The latest report gives investors a reason to take the turnaround seriously: Q2 revenue of $2.85 billion rose 13% reported and 11% organic, adjusted EPS climbed 40%, and adjusted EBITDA rose 28% to $1,075 million. In simple terms, the business is growing faster and keeping more of each extra dollar.

The broader portfolio is helping

The key shift is not one strong quarter by itself. It is that the wider group kept improving while B+L accelerated. Even excluding B+L, Bausch Health posted its 13th straight quarter of revenue growth. That suggests the improvement is not just a one-unit miracle.

The next test is repeatability

The market's next question is straightforward: can B+L do it again? Management did more than post solid numbers; it also raised full-year 2026 guidance. That raises the burden of proof for the next report. If growth and margins keep moving higher, investors can justify paying more for a real turnaround. If not, this quarter may look more like a strong data point than a new valuation base.

Why the numbers improved: pricing, mix, and cost discipline

This stronger quarter is easier to explain. The results look healthier because the business seems to be charging better prices, selling a stronger product mix, and controlling costs more tightly.

Profit can grow faster than sales when mix improves

If revenue rises because more customers buy higher-margin products, profit can grow faster than sales even if volume growth is modest. Bausch + Lomb already showed that pattern in Q1, when revenue grew 9% as reported and 6% on a constant currency basis and adjusted EBITDA reached $189 million. Revenue was moving up, but the bigger clue was the earnings power coming through on a relatively small base.

By Q2, that effect was clearer. The company delivered revenue up 13% on a reported basis and 11% on an organic basis, while adjusted earnings per diluted share increased 40% and adjusted EBITDA rose 28%. That is what investors want to see in a turnaround: not just more units sold, but better margin on those sales.

Cash flow helps confirm the earnings trend

Price increases and better mix only matter if they translate into usable cash. Here, the cash story is starting to line up with the earnings story. Bausch Health excluding B+L generated $517 million in cash provided by operating activities and $471 million in adjusted cash flows from operations in Q2. That gives the company more flexibility to reduce debt, keep investing, and withstand weaker demand.

The broader group still matters, too. The non-B+L business has now posted a thirteenth consecutive quarter of year-over-year revenue growth, which lowers the chance that B+L's improvement is only a one-quarter outlier.

The caveat: adjusted figures can look cleaner than GAAP

Investors should still keep one foot on the ground. The headline EPS jump is an adjusted, non-GAAP number, and management notes that adjusted earnings per diluted share and related measures require reconciliation to GAAP. Adjusted figures are useful, but they can smooth out problems that GAAP shows more plainly. The clearest check next quarter is simple: does operating cash flow stay strong, and does the broader earnings picture continue to improve?

The valuation debate is about durability, not direction

The valuation fight is no longer about whether things are getting better. It is about whether B+L's improvement is clean enough to pay for now, or whether the stock has already priced in too much of the recovery. Bulls can point to a clear operating trend: early gains were followed by another step-up, with revenue up 13% on a reported basis and 11% on an organic basis. Bears do not need to prove the turnaround is fake. Their case is simpler: if the rebound has relied too heavily on pricing and discipline while GAAP earnings remained weak, investors may be paying for recovery before it is fully earned.

The bull case: the early gains may be sticky

The bull case rests on repeatability, not perfection. In Q1, B+L already showed a better pattern, with revenue grew 9% as reported and 6% on a constant currency basis and adjusted EBITDA of $189 million. Q2 suggested that was not a fluke. That matters because a stock can rerate not just from growth, but from improved confidence that the growth is sturdier than the market expected.

The bear case: the GAAP base is still fragile

The bear case is less about direction than about quality. Bausch + Lomb previously posted a GAAP net loss attributable to Bausch + Lomb of $71 million. At the parent level, the picture was even cloudier, with GAAP net loss attributable to Bausch Health of $1,423 million, inclusive of a $1,426 million goodwill impairment charge. That is the real tension: bulls see a business learning to convert growth into profit, while bears see a company that may still be buying valuation with pricing moves and cost control rather than fully clean earnings power.

What the next report needs to prove

If the next quarter looks like a continuation rather than a spike, the bullish case gets much easier to support. The key watchpoints are straightforward:

• Revenue growth stays firm rather than fading after this step-up.
• Adjusted EBITDA and EPS keep improving without leaning too hard on one-time adjustments.
• Operating cash flow remains strong enough to support balance-sheet repair and ongoing investment.
• The non-B+L business continues to support the group instead of masking weakness elsewhere.

Positioning takeaway: B+L looks more credible after Q2, but the stock still needs more quarters of consistent execution before a higher valuation is fully justified.